DC-LC3in-D5 |
| Catalog No.GC65191 |
DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination treatments in cancer through inhibiting autophagy[1].
DC-LC3in-D5 demonstrates high selectivity to LC3A/B in the proteome. DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells[1].Treatment of HeLa cells with DC-LC3in-D5 (3-30 μM) results in disruption of LC3B lipidation, inhibition of autophagic vesicle formation, and accumulation of p62[1].
[1]. Shijie Fan, et al. Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein. Angew Chem Int Ed Engl. 2021 Dec 6;60(50):26105-26114.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *